pharmaphorum

APRIL 21, 2021

The UK biotechnology company is aiming to transform the development of cell therapies using a systematic direct cell conversion & maintenance platform powered by big-data. The post Big data and cell therapy development: the pharmaphorum podcast appeared first on.

Big Data 52

Big Data Development Gene Editing Life Science 52

Drug Discovery World

DECEMBER 20, 2022

As 2022 draws to a close, life sciences market analysts attempt to correctly predict what the next 12 months might bring to the drug discovery sector. In summary, 2023 could be a very exciting year for life sciences. DDW’s Diana Spencer summarises the key trends likely to impact the market in 2023. .

Drugs 52

Drugs Gene Editing Clinical Trials Clinical Trials 52

XTalks

AUGUST 2, 2023

With Blackstone Life Sciences, up to €300 million (around $315 million USD) will be invested to accelerate pivotal studies and clinical development programs for formulating the subcutaneous delivery of the anti-CD38 antibody Sarclisa (isatuximab) for the treatment of multiple myeloma. 21) Merck KGaA By: Ayesha Rashid, Ph.D.

Sales 98

Sales Manufacturing FDA Approval Life Science 98